Late stage research pipeline

In addition to its rich clinical development pipeline, UCB has a range of new molecules, both small and large, in late stage research or pre-clinical development and additional molecules at an earlier stage of discovery research.

All of these molecules are in UCB's three key therapeutic areas of neurology, inflammation and oncology, addressing the following conditions:


CNS	epilepsy cognition dementia neuropathic pain multiple sclerosis
Inflammation	TNF-mediated disease such as rheumatoid arthritis, inflammatory bowel disease (IBD) and psoriasis allergy and severe asthma systemic lupus erythematosus (SLE) immunomodulators
Oncology	solid tumours

CNS

Inflammation

TNF-mediated disease such as rheumatoid arthritis, inflammatory bowel disease (IBD) and psoriasis

allergy and severe asthma

systemic lupus erythematosus (SLE)

immunomodulators

Oncology

solid tumours